FoundationOne OK’ed as a CDx for Opdivo/Keytruda’s MSI-High Use: Chugai

Chugai Pharmaceutical said on June 22 that it has won an additional indication in Japan for FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for the PD-1 inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) for their use in microsatellite instability...read more